| Changes in recommendations - Glycoprotein IIb/IIIa Inhibitors | |||||
|---|---|---|---|---|---|
| 2014 Guideline | 2020 Guideline | ||||
| Glycoprotein (GP) IIb/IIIa inhibitors should be used in patients with recurrent ischemic symptoms despite double oral platelet antiaggregation and anticoagulation. | IIa | C | In the conservative strategy, adjunct tirofiban can be used in patients with recurrent ischemic symptoms despite treatment with double oral platelet antiaggregation and anticoagulation. | IIb | C |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.